In the BioHarmony Drug Report Database
Dupilumab
Dupixent (dupilumab) is an antibody pharmaceutical. Dupilumab was first approved as Dupixent on 2017-03-28. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat atopic dermatitis. The pharmaceutical is active against interleukin-4 receptor subunit alpha. In addition, it is known to target Interleukin-4 receptor subunit alpha.
Trade Name
|
Dupixent |
|---|---|
Common Name
|
dupilumab |
ChEMBL ID
|
CHEMBL2108675 |
Indication
|
atopic dermatitis |
Drug Class
|
Monoclonal antibodies: fully human, immunomodulating |
Image (chem structure or protein)
